natgillin/translations-raw huggingface dataset:
Tell the doctor requesting these tests that you have recently been given Celvapan.
Povejte zdravniku, ki je naročil te preiskave, da ste bili pred kratkim cepljeni s cepivom Celvapan.
It should be noted that the adverse reactions may be intensified.
Zavedati se je treba, da so neželeni učinki lahko izrazitejši.
ADR frequency is based upon the following scale: Very Common (≥ 1/10); Common (≥ 1/100< 1/10), Uncommon (≥ 1/1,000 - < 1/100), Rare (≥ 1/10,000 - < 1/1,000), Very Rare (< 1/10,000)
Pogostost neželenih učinkov temelji na naslednji lestvici: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000)
The safety of Celvapan in pregnancy and lactation has been assessed in a limited number of pregnant
Varnost zdravila Celvapan v nosečnosti in obdobju dojenja je bila preverjena pri majhnem številu
A protective response may not be elicited in all vaccinees (see section 5.1).
S cepljenjem verjetno ne boste izzvali zaščitnega odziva pri vseh cepljenih osebah (glejte poglavje 5.1).
Children aged less than 6 months Vaccination is not currently recommended in this age group.
Otroci, mlajši od 6 mesecev Pri tej starostni skupini cepljenje trenutno ni priporočljivo.
Very common: Feeling tired, headache
Zelo pogosti: utrujenost, glavobol
The other ingredients are: trometamol, sodium chloride, water for injections, polysorbate 80.
Pomožne snovi so: trometamol, natrijev klorid, voda za injekcije, polisorbat 80.
Do not use Celvapan after the expiry date which is stated on the carton.
Cepiva Celvapan ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
Your doctor or nurse will administer the vaccine in accordance with official recommendations.
Cepivo vam bo dal zdravnik ali medicinska sestra v skladu z uradnimi priporočili.
Allergic reactions, including anaphylactic reactions leading to a dangerous decrease in blood pressure which, if untreated, may lead to shock.
alergijske reakcije, vključno z anafilaktičnimi reakcijami, ki so povzročile nevaren padec krvnega tlaka, ki lahko vodi v šok, če ni zdravljen.
• The MAH shall agree with Member States to measures facilitating the identification and traceability of the A/(H1N1)v vaccine administered to each patient, in order to minimise medication errors and aid patients and health care professionals to report adverse reactions.
• Imetnik dovoljenja za promet se bo z državami članicami dogovoril o ukrepih za lažjo identifikacijo in sledljivost cepiva A/(H1N1)v, uporabljenega pri posameznem bolniku, da bi čim bolj zmanjšali napake pri uporabi cepiva ter v pomoč bolnikom in zdravnikom pri poročanju o neželenih učinkih.
Allergic reactions may occur following vaccination, in rare cases leading to shock.
Po cepljenju se lahko pojavijo alergijske reakcije, ki so v redkih primerih povzročile šok.
Such alterations in liver function have not been seen to date in human clinical studies.
Takšnih sprememb delovanja jeter doslej še niso opazili v kliničnih študijah pri ljudeh.
• The minimal data elements to be transmitted in individual case safety reports in order to facilitate the evaluation and the identification of the vaccine administered to each subject, including the invented name, the vaccine manufacturer and the
• Minimalne podatkovne elemente, ki jih je treba sporočiti v vsakem poročilu, da se olajša vrednotenje in identifikacija uporabljenega cepiva pri posamezni osebi, vključno z imenom cepiva, izdelovalcem in številko serije.
What you need to know before you receive Celvapan
Kaj morate vedeti, preden boste cepljeni s cepivom Celvapan
Children and adolescents aged 3 to 17 years One dose of 0.5 ml at an elected date.
Otroci in mladostniki od 3 do 17 let En odmerek 0,5 ml na izbran datum.
Detailed information on this medicinal product is available on the website of the European Medicines
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA)
PSYCHIATRIC DISORDERS
PSIHIATRIČNE MOTNJE
Shake before use.
Pred uporabo pretresite.
* propagated in Vero cells (continuous cell line of mammalian origin)
* razmnožen v celicah Vero (neprekinjena celična linija sesalskega izvora)
Therefore, healthcare providers need to assess the benefits and potential risks of administering the vaccine in individuals with thrombocytopenia or any bleeding disorder that would contraindicate intramuscular injection unless the potential benefit outweighs the risk of bleedings.
Zato mora zdravnik oceniti koristi in morebitna tveganja cepljenja oseb s trombocitopenijo ali motnjami strjevanja krvi, ki bi povzročile kontraindikacije za intramuskularno injiciranje, razen če morebitni koristni učinki odtehtajo tveganje
Name and address of the manufacturers of the biological active substance(s)
Ime in naslov izdelovalca biološke zdravilne učinkovine (učinkovin)
Most of the reactions were mild in nature, of short duration and qualitatively similar to those induced by influenza vaccines.
Večina neželenih učinkov je bilo blagih, kratkotrajnih in glede na zvrst podobnih tistim, ki jih povzročijo cepiva proti gripi.
However, if this cannot be avoided, the vaccines should be injected into separate limbs.
Če se temu ni mogoče izogniti, je treba cepiva injicirati v različne okončine.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.
Kot pri vseh cepivih za injiciranje morata biti vedno takoj na voljo ustrezno medicinsko zdravljenje in zdravniški nadzor, če bi po cepljenju prišlo do sicer redke anafilaktične reakcije.
Immune response against A/California/07/2009(H1N1)v
Odziv imunskega sistema na sev A/California/07/2009(H1N1)v
Prophylaxis of influenza caused by A(H1N1)v 2009 virus (See section 4.4).
Preprečevanje gripe, ki jo povzroča virus A(H1N1)v 2009 (glejte poglavje 4.4).
Vaccination is not currently recommended in this age group.
Pri tej starostni skupini cepljenje trenutno ni priporočljivo.
In an observational safety study including 3216 subjects aged 6 months to 60 years and older, the nature of adverse events was consistent with those observed in other clinical studies in adults and children.
V opazovalni varnostni študiji, v katero je bilo vključenih 3216 oseb, starih od 6 mesecev do 60 let in več, je bila narava neželenih učinkov skladna z neželenimi učinki, opaženimi v drugih kliničnih študijah pri odraslih in otrocih.
Following influenza vaccination, false positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus, and especially, HTLV-1.
Po cepljenju proti gripi so poročali o lažno pozitivnih rezultatih seroloških testov na osnovi metode ELISA za določanje protiteles proti virusu humane imunske pomanjkljivosti (HIV-1), virusu hepatitisa C in še posebej virusu HTLV-1.
If you have any further questions, ask your doctor or nurse.
Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom ali medicinsko sestro.
These transitory false-positive results may be due to IgM production in response to the vaccine.
Prehodno lažno pozitivni rezultati so lahko posledica nastajanja protiteles IgM kot odziv
Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity.
Podatki od nosečnic, cepljenih z različnimi inaktiviranimi sezonskimi cepivi brez adjuvansa, pa niso pokazali malformacij ali toksičnosti cepiva za plod ali novorojenčka.
The vaccine is a clear to opalescent, translucent suspension.
Cepivo je bistra do opalescentna, prosojna suspenzija.
One dose of 0.5 ml at an elected date.
En odmerek 0,5 ml na izbran datum.
A dose (0.5 ml) of the vaccine will be given.
Prejeli boste en odmerek (0,5 ml) cepiva.
2nd Dose
2. odmerku
There are no safety, immunogenicity or efficacy data to support interchangeability of Celvapan with other (H1N1)v vaccines.
Ni podatkov o varnosti, imunogenosti ali učinkovitosti, ki bi potrjevali zamenljivost cepiva Celvapan z drugimi cepivi proti (H1N1)v.
• Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest
• Neželene učinke, ki imajo pri prijavljanju prednost, tj. smrtne in življenje ogrožajoče neželene učinke, nepričakovane hude neželene učinke, neželene učinke posebnega pomena (AESI).
Side effects from clinical studies in adults and older people
Neželeni učinki iz kliničnih študij pri odraslih in starostnikih
Animal reproductive toxicology studies do not indicate harmful effects in regard to female fertility, embryo-foetal and pre- and post-natal toxicity.
Študije toksičnosti za razmnoževanje na živalih ne kažejo škodljivih učinkov glede plodnosti samic, razvoja zarodka in ploda ter predporodne in poporodne toksičnosti.
Uferstrasse 15
Baxter AG Uferstrasse 15
Immunisation should be carried out by intramuscular injection preferably into the deltoid muscle or anterolateral thigh, depending on the muscle mass.
Cepivo je treba injicirati intramuskularno, najbolje v deltoidno mišico oziroma v anterolateralni del stegna, odvisno od mišične mase osebe.
Preferred MedDRA Term
Prednostni izraz MedDRA
• The MAH shall agree with Member States on the provision of a targeted communication to health care professionals which should address the following:
• Imetnik dovoljenja za promet se bo z državami članicami dogovoril o zagotavljanju ciljnega obveščanja za zdravnike, ki mora obravnavati naslednje:
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET
A minor infection such as a cold should not be problem, but your doctor or nurse should advise whether you could still be vaccinated with Celvapan.
Manjša okužba, kot je na primer prehlad, po navadi ni težava, kljub temu pa poslušajte nasvet zdravnika ali medicinske sestre glede cepljenja s cepivom Celvapan;
12 to 35 months
od 12 do 35 mesecev
The dose recommendations take into account available data from clinical studies in healthy subjects who received two doses of Celvapan (H1N1)v.
Priporočila za odmerjanje upoštevajo dostopne podatke potekajočih kliničnih študij pri zdravih preiskovancih, ki so dobili dva odmerka cepiva Celvapan (H1N1)v.
In a study with a similar influenza vaccine (containing a H5N1 vaccine strain) that included healthy adults and older people, subjects with a weakened immune system and patients with long-term conditions, the safety profile was similar to that in healthy adults.
V študiji s podobnim cepivom proti gripi (ki je vsebovalo cepilni sev H5N1), v katero so bili vključeni zdravi odrasli in starostniki, preiskovanci z oslabljenim imunskim sistemom in bolniki z dolgotrajnimi boleznimi, je bil varnostni profil podoben kot pri zdravih odraslih.
DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET
Frequency1
Pogostnost1
Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome.
Nevrološke motnje, kot so encefalomielitis, nevritis in Guillain-Barréjev sindrom.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA
• Side effects observed during post-marketing surveillance
• Neželeni učinki, opaženi v obdobju trženja cepiva
The following adverse reactions were reported at a higher frequency category than in
Naslednji neželeni učinki so bili opaženi z večjo pogostnostjo kot v
• The MAH shall agree with Member States on mechanisms allowing patients and health care professionals to have continuous access to updated information regarding Celvapan.
• Imetnik dovoljenja za promet se bo z državami članicami dogovoril o mehanizmih, ki bodo bolnikom in zdravstvenim delavcem omogočili stalen dostop do posodobljenih
After first opening the vial is to be used within a maximum of 3 hours.
Po prvem odprtju uporabite vialo v največ 3 urah.
• you have a bleeding condition or a bleeding problem or you bruise easily.
• če imate težave s krvavitvami ali zlahka dobite podplutbe.
Ask your pharmacist what to do with medicines you no longer use.
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
Whole virion influenza vaccine, inactivated, containing antigen of strain*: 7.5 micrograms**
Cepivo proti gripi s celimi inaktiviranimi virusi, ki vsebuje antigen seva*: 7,5 mikrograma**
4.7 Effects on ability to drive and use machines Some undesirable effects mentioned under section 4.8 “Undesirable effects” may affect the ability to
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Na sposobnost vožnje in upravljanja s stroji lahko vplivajo določeni neželeni učinki, ki so navedeni
Crude vaccine effectiveness of one dose of pandemic vaccine among children was 100% (95%
Neobdelana učinkovitost cepiva z enim odmerkom pandemskega cepiva pri otrocih je bila 100 % (95-odstotni interval zaupanja: 70-100 %).
Pandemic vaccine effectiveness against the medically-attended influenza like illness (ILI) with laboratory-confirmation as A(H1N1)v, was assessed for the vaccination campaign in Jersey 2009/2010 in a case control study (test-negative design).
Učinkovitosti pandemskega cepiva proti gripi podobni bolezni z medicinsko oskrbo in laboratorijsko potrditvijo A(H1N1)v so ugotavljali med cepilno kampanjo 2009/2010 v Jerseyu v obliki študije primerov in kontrol (negativna testna zasnova).
There were no reported vaccine failures in either of these paediatric age groups.
V nobeni pediatrični starostni skupini niso ugotovili neuspešnih cepljenj.
The safety profile in healthy subjects > 60 years of age, in immune-compromised subjects and patients with chronic disease conditions is similar to the safety profile in healthy subjects.
Varnostni profil pri zdravih osebah, starejših od 60 let, imunsko kompromitiranih osebah in bolnikih s kroničnimi boleznimi je bil podoben kot pri zdravih osebah.
* MN titre ≥ 1:40 ** > 4-fold increase in MN titre *** geometric mean increase
* titer MN ≥1:40 ** >4-kratno povečanje titra MN *** geometrična sredina povečanja
Immunisation shall be postponed in patients with severe febrile illness or acute infection.
Cepljenje je treba odložiti pri bolnikih, ki imajo hujše obolenje z zvišano telesno temperaturo ali
From post-marketing surveillance with egg-derived trivalent seasonal influenza vaccines, the following serious adverse reactions have been reported:
Med spremljanjem trivalentnih cepiv proti sezonski gripi izdelanih na jajcih po pridobitvi dovoljenja za promet so poročali o naslednjih resnih neželenih učinkih:
The vaccine may be used during breast-feeding.
Cepivo Celvapan lahko dobite med dojenjem.
Younger children 6 months to 9 years received Celvapan, while older children from 9 to 18 years of age received an adjuvanted split pandemic vaccine.
Manjši otroci, stari od 6 mesecev do 9 let, so prejeli cepivo Celvapan, večji otroci, stari od 9 do 18 let, so prejeli pandemsko cepivo z razcepljenim virionom in adjuvansom.
• Safety and immunogenicity data in special risk groups (immunocompromised and
• Podatki o varnosti in imunogenosti pri skupinah s posebnim tveganjem (imunsko kompromitiranih osebah in bolnikih s kroničnimi boleznimi).
It is recommended that subjects who receive a first dose of Celvapan, complete the vaccination course with Celvapan (see section 4.4).
Priporočljivo je, da osebe, ki prejmejo prvi odmerek cepiva Celvapan, cepljenje tudi zaključijo s cepivom Celvapan (glejte poglavje 4.4).
• Clinical trials with a version of Celvapan containing a H5N1 vaccine strain
• Klinična preskušanja z različico cepiva Celvapan, ki vsebuje sev cepiva proti H5N1
“Possible side effects” may affect your ability to drive or use
Nekateri učinki, ki so navedeni v poglavju 4 »Možni neželeni učinki«, lahko vplivajo na vašo sposobnost vožnje in upravljanja s stroji.
When Celvapan is given for the first dose, it is recommended that Celvapan (and not another vaccine against (H1N1)v) be given for the complete vaccination course.
Če je za prvi odmerek uporabljeno cepivo Celvapan, je priporočljivo, da se cepljenje tudi dokonča s cepivom Celvapan (in ne z drugim cepivom proti (H1N1)v).
In such cases, you should be aware that the side effects may be more intense.
V takih primerih se morate zavedati, da so neželeni učinki
If any of these side effects occur, please tell your doctor or nurse immediately.
Če se pojavi katerikoli od teh neželenih učinkov, nemudoma obvestite svojega zdravnika ali medicinsko sestro.
• generalized skin reactions including urticaria (hives)
• splošne kožne reakcije, kot je urtikarija (koprivnica);
*Such reactions have been manifested by respiratory distress, hypotension, tachycardia, tachypnea, cyanosis, pyrexia, flushing, angioedema, and urticaria Musculoskeletal and connective tissue disorders:
*Takšne reakcije se lahko kažejo z dihalno stisko, hipotenzijo, tahikardijo, tahipnejo, cianozo, zvišano telesno temperature, vročinskimi oblivi, angioedemom in urtikarijo.
Following a 12-month booster vaccination with a licensed trivalent virosomal influenza vaccine for the 2010/2011 Northern hemisphere influenza season, seroprotection rates, seroconversion rates and serconversion factors (compared to pre-booster antibody levels) for the H1N1 component as measured by SRH and MN assays were as follows:
Po cepljenju z 12-mesečnim poživitvenim odmerkom s trivalentnim cepivom proti gripi z dovoljenjem za promet za sezono gripe na severni polobli v l. 2010/2011 so bili odstotki serozaščite, serokonverzije in faktorji serokonverzije (v primerjavi z ravnmi protiteles pred poživitvenim odmerkom) za komponento H1N1, izmerjeni s testoma SRH in MN, naslednji:
• vasculitis (inflammation of blood vessels which can cause skin rashes, joint pain and kidney
• vaskulitis (vnetje krvnih žil, ki lahko povzroči kožni izpuščaj, sklepne bolečine in težave z ledvicami),
Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling
Med znake alergijske reakcije sodijo srbeč kožni izpuščaj, težko dihanje in otekanje
Celvapan (H1N1)v to healthy children aged 6 months to 17 years.
Celvapan (H1N1)v zdravim otrokom, starim od 6 mesecev do 17 let.
Neuralgia, paraesthesia, transient thrombocytopenia.
Nevralgija, parestezije, prehodna trombocitopenija
20 multidose vials (10 doses per vial - 0.5 ml per dose)
20 večodmernih vial (10 odmerkov na vialo - 0,5 ml na odmerek)
Each vaccine dose of 0.5 ml is withdrawn into a syringe for injection.
Vsak odmerek cepiva po 0,5 ml potegnite v brizgo za injiciranje.
All subjects
Vsi preiskovanci
From clinical studies limited immunogenicity and safety data are available for Celvapan (H1N1)v in healthy adult and older subjects and in children (see section 4.4, 4.8, and 5.1).
Iz kliničnih študij je bilo pridobljeno malo podatkov o imunogenosti in varnosti cepiva Celvapan (H1N1)v pri odraslih, starostnikih in otrocih (glejte poglavja 4.4, 4.8. in 5.1).
Celvapan should under no circumstances be administered intravascularly.
Cepiva Celvapan ne smete v nobenem primeru injicirati v žilo.
There were fewer reactions after the second dose of the vaccine compared with the first dose.
Po drugem odmerku cepiva je bilo manj neželenih učinkov kot po prvem.
What Celvapan looks like and contents of the pack Celvapan is a clear to opalescent, translucent liquid.
Izgled cepiva Celvapan in vsebina pakiranja Cepivo Celvapan je bistra do opalescentna in prosojna tekočina.
If you are not sure, talk to your doctor or nurse before having this vaccine.
Če ste negotovi, se pred cepljenjem posvetujte s svojim zdravnikom ali medicinsko sestro.
Pandemic Observational Study with Celvapan (H1N1)v
Pandemska opazovalna študija s cepivom Celvapan (H1N1)v
Celvapan (H1N1)v to healthy adults aged 18 years and older.
Celvapan (H1N1)v zdravim odraslim osebam, starim vsaj 18 let.
Adults aged 18 years and older
Odrasli, stari vsaj 18 let
Alterations in calcium metabolism have not been examined in human clinical studies.
Spremembe presnove kalcija niso bile raziskane v kliničnih študijah pri
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
In children aged 6 to 35 months disturbed sleep and fever were very common, and decreased appetite, restlessness, irritability, crying and drowsiness were common.
Pri otrocih, starih od 6 do 35 mesecev, so zelo pogosto poročali o motnjah spanja in zvišani telesni temperaturi, pogosto pa o izgubi apetita, nemirnosti, razdražljivosti, jokanju in zaspanosti.
The vaccine should never be
Cepiva nikoli ne smete dobiti v veno.
After first opening, the product should be used immediately.
Zdravilo uporabite nemudoma po prvem odprtju.
Tell your doctor if you are pregnant, think you may be pregnant, or are planning to have a baby.
Če ste noseči, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte s svojim zdravnikom, preden se cepite s cepivom Celvapan.
A second dose of the vaccine should be given after an interval of at least three weeks.
Drugi odmerek cepiva je treba dati po časovnem razmiku najmanj treh tednov.
QUALITATIVE AND QUANTITATIVE COMPOSITION Whole virion influenza vaccine, inactivated containing antigen of strain *:
KAKOVOSTNA IN KOLIČINSKA SESTAVA Cepivo proti gripi z inaktiviranimi virusi, ki vsebuje antigen seva*:
One pack of Celvapan contains 20 multidose vials of 5 ml suspension for injection for 10 doses.
Eno pakiranje cepiva Celvapan vsebuje 20 večodmernih vial po 5 ml suspenzije, za
The use of Celvapan may be considered during pregnancy if this is thought to be necessary, taking into
Če menite, da je potrebno, lahko cepivo Celvapan uporabljate tudi v času nosečnosti, ob upoštevanju
Hypersensitivity reactions, including anaphylaxis, have been reported following CELVAPAN vaccination (see section 4.8).
Pri uporabi cepiva Celvapan so se pojavile preobčutljivostne reakcije, vključno z anafilakso (glejte poglavje 4.8).
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Multidose vial (10 doses of 0.5 ml per vial)
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT večodmerna viala (10 odmerkov po 0,5 ml)
Very common: Injection site pain, injection site redness, muscle pain
Zelo pogosti: bolečine na mestu injiciranja, pordelost na mestu injiciranja, bolečine v mišicah
Other sources of information
Dodatne informacije);
Very common: Pain and redness where the injection was given, aching muscles Uncommon: Influenza like illness
Zelo pogosti: bolečine in pordelost na mestu injiciranja, bolečine v mišicah Občasni: gripi podobna bolezen
There is no information on administration of the vaccine Celvapan with other vaccines.
Ni podatkov o uporabi cepiva Celvapan z drugimi cepivi.
OTHER SPECIAL WARNING(S), IF NECESSARY Do not inject intravascularly.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Cepiva ne smete injicirati v žilo.
Specifically, headache, vertigo (spinning feeling), cough, feeling sick, vomiting, diarrhoea, pain in the arms or legs and tiredness were observed commonly in children and adolescents.
Glavobol, vrtoglavica, kašelj, slabo počutje, bruhanje, driska, bolečine v rokah ali nogah in utrujenost so bili pri otrocih in mladostnikih
• Post-marketing surveillance
• Spremljanje po pridobitvi dovoljenja za promet
Safety data after the first and second vaccination suggest a similar safety profile to that reported for the influenza vaccines
Podatki o varnosti po prvem in drugem cepljenju kažejo podoben varnostni profil kot pri cepivih proti gripi s sevom H5N1.
Additionally, in the case of the 9 to 17 year olds pain at the injection site was very common.
Poleg tega so bile bolečine na mestu injiciranja pri otrocih in mladostnikih, starih od 9 do 17 let, zelo
The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.
Če bolnik prejema imunosupresivno zdravljenje, je imunski odziv lahko manjši.
Such reactions have occurred both in patients with a history of multiple allergies and in patients with no known allergy.
Takšne reakcije so je pojavile tako pri osebah z več alergijami v anamnezi, kot tudi pri